These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23788306)

  • 1. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function.
    Pellicori P; Torromeo C; Barillà F; Mangieri E; Evangelista A; Truscelli G; Costanzo P; Hoye A; Wong K
    Cardiol J; 2013; 20(3):310-7. PubMed ID: 23788306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 1-year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein IIb/IIIa Inhibitors.
    Kassaian SE; Fathi Y; Lotfi-Tokaldany M; Salarifar M; Alidoosti M; Haji-Zeinali AM; Aghajani H; Amirzadegan A; Nozari Y; Mortazavi SH; Jalali A; Saroukhani S
    Crit Pathw Cardiol; 2016 Sep; 15(3):89-94. PubMed ID: 27465002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
    Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
    Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
    Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
    Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
    Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
    Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
    Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
    Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
    Friedland S; Eisenberg MJ; Shimony A
    Am J Cardiol; 2011 Nov; 108(9):1244-51. PubMed ID: 22000626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Kini AS; Chen VH; Krishnan P; Lee P; Kim MC; Mares A; Suleman J; Moreno PR; Sharma SK
    Am Heart J; 2008 Sep; 156(3):513-9. PubMed ID: 18760134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shimada YJ; Nakra NC; Fox JT; Kanei Y
    Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C; Erkol A; Pala S; Oduncu V; Dündar C; İzgi A; Tigen K; Gibson CM
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):59-67. PubMed ID: 21523892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
    Xu Q; Yin J; Si LY
    Int J Cardiol; 2013 Jan; 162(3):210-9. PubMed ID: 22769575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.
    Ali-Hasan-Al-Saegh S; Mirhosseini SJ; Shahidzadeh A; Rahimizadeh E; Sarrafan-Chaharsoughi Z; Ghodratipour Z; Lotfaliani M; Rezaeisadrabadi M; Dehghan HR; Bireta C; Weymann A; Sabashnikov A; Popov AF
    Kardiol Pol; 2016; 74(2):104-18. PubMed ID: 26202532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis of Randomized Trials of Intracoronary Versus Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Elbadawi A; Elgendy IY; Megaly M; Ha LD; Mahmoud K; Alotaki E; Ogunbayo GO; Baig B; Abuzaid AS; Saad M; Depta JP
    Am J Cardiol; 2017 Oct; 120(7):1055-1061. PubMed ID: 28826897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
    Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.